**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 53707

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Multi-modal radiomics model to predict treatment response to** **neoadjuvant chemotherapy for locally advanced rectal cancer**

Li ZY *et al.* Multi-modal radiomics model for LARC

Zheng-Yan Li, Xiao-Dong Wang, Mou Li, Xi-Jiao Liu, Zheng Ye, Bin Song, Fang Yuan, Yuan Yuan, Chun-Chao Xia, Xin Zhang, Qian Li

**Zheng-Yan Li, Mou Li, Xi-Jiao Liu, Zheng Ye, Bin Song, Fang Yuan, Yuan Yuan, Chun-Chao Xia,** Department of Radiology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China

**Xiao-Dong Wang, Qian Li,** Department of Gastrointestinal Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China

**Xin Zhang,** Life Science, PDx, IPM team, GE Healthcare, Shanghai 210000, China

**Author contributions:** All authors helped to perform the research; Li ZY wrote the manuscript and performed the procedures and data analysis; Li ZY and Wang XD conceived of and designed the study, and performed the experiments and data analysis; Song B contributed to writing of the manuscript and to conception and design of the study; Li M, Ye Z, Yuan F and Liu XJ contributed to writing of the manuscript; Yuan Y, Xia CC, Li Q and Zhang X performed the data collection and data analysis.

**Supported by** Research Grant of National Nature Science Foundation of China, No. 81971571; Multimodal MR Imaging and Radiomics of Rectal Cancer, Science and Technology Department of Sichuan Province, No. 2019YFS0431; and Sichuan University Training Program of Innovation and Entrepreneurship for Undergraduates, No. C2019104739.

**Corresponding author: Bin Song, MD, PhD,** **Chief Doctor, Professor,** Department of Radiology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu 610041, Sichuan Province, China. songlab\_radiology@163.com

**Received:** December 30, 2019

**Revised:** March 27, 2020

**Accepted:** April 21, 2020

**Published online:**

**Abstract**

BACKGROUND

Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging.

AIM

To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC.

METHODS

This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set (*n* = 70) and a validation set (*n* = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve analysis. This was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram.

RESULTS

Eighty out of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC = 0.859, ACC = 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.812, ACC = 0.792) sets. The combined radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation.

CONCLUSION

A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC.

**Key words:** Radiomics; Rectal cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; Computed tomography

Li ZY, Wang XD, Li M, Liu XJ, Ye Z, Song B, Yuan F, Yuan Y, Xia CC, Zhang X, Li Q. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. *World J Gastroenterol* 2020; In press

**Core tip:** Our study developed and validated a radiomics model that incorporated computed tomography and magnetic resonance imaging radiomics features for noninvasive and individualized prediction of clinical response to neoadjuvant chemotherapy in patients with locally advanced rectal cancer. The combination of computed tomography and magnetic resonance imaging radiomics features was associated with better performance than any individual sequence. In contrast, the clinical model based on extramural venous invasion achieved relatively low diagnostic performance. The multi-modal nomogram facilitated the easy and noninvasive estimation of clinical response to neoadjuvant chemotherapy. The proposed radiomics model performs well, thereby guiding clinical decision-making and preoperative assessment of neoadjuvant chemotherapy for locally advanced rectal cancer.

**INTRODUCTION**

With the improvement in inspection technology and implementation of the concept of individualized treatment, the early detection rate of rectal cancer has markedly increased[[1](#_ENREF_1)]. However, the postoperative recurrence rate of locally advanced rectal cancer (LARC) is high, leading to poor prognosis, and neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is recommended for LARC[[2](#_ENREF_2),[3](#_ENREF_3)]. As previously reported[[2](#_ENREF_2),[4-6](#_ENREF_4)], neoadjuvant CRT can downstage the rate of LARC by 50-60%, and achieve a pathological complete response (PCR) rate of 15-27%.

However, several studies[[7-10](#_ENREF_7)] have reported that there were still 7-37% of LARC patients who do not respond to neoadjuvant CRT, which may not only increase CRT-related side effects and economic burden, but also delay surgery time. Furthermore, non-responders were associated with lower recurrence-free survival rate, distant metastasis, and local recurrence rate compared with good responders[[11](#_ENREF_11)]. Therefore, it is necessary to identify which patients can benefit from neoadjuvant CRT treatment.

Enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are recommended and commonly used for LARC[[3](#_ENREF_3)] to noninvasively evaluate the therapeutic responses to neoadjuvant CRT. Different imaging techniques have been reported to identify the response to neoadjuvant CRT, including fluorodeoxyglucose positron emission tomography (FDG PET), T2-weighted MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging (DWI); however, their performance is varied and limited[[12-15](#_ENREF_12)]. Thus, there is an increasing need to identify a more reliable method for evaluating therapeutic response.

Radiomics, which involves computer-based extraction of a large number of quantitative imaging features, are analyzed with a specific clinical question in mind to help clinical decision-making[[16](#_ENREF_16)]. There are several reports of the successful use of radiomics analysis for the classification of benign and malignant tissue[[17](#_ENREF_17)], adding information about tumor aggressiveness[[18-20](#_ENREF_18)], and predicting responsiveness to neoadjuvant CRT prior to initiation[[21](#_ENREF_21),[22](#_ENREF_22)]. We hypothesize that CT and MRI-based radiomics may add value in the evaluation of therapeutic responses to neoadjuvant chemotherapy in patients with LARC; thus, improving qualitative assessment will help differentiate patients with a clinical response from those with no response after neoadjuvant chemotherapy.

The aim of this retrospective study was to create a multi-modal radiomics model derived from CT and MRI, and to investigate the added value for predicting clinical response in patients with LARC after neoadjuvant chemotherapy.

**MATERIALS AND METHODS**

***Patients***

This study was approved by the Ethics Committee of West China Hospital of Sichuan University (No. 2019-140). Patient approval or informed consent for the review of medical images was not required.

LARC was defined as the primary tumor invading the muscularized layer of the intestinal wall (T3-4), with or without peripheral lymph node metastasis (N0-2), and without distant metastasis, as detected by imaging or pathological examination[[23](#_ENREF_23)]. We retrospectively included patients with LARC who underwent total TME after neoadjuvant chemotherapy in the Gastrointestinal Surgery Department of our hospital from October 2016 to June 2019. Inclusion criteria were: (1) rectal MRI and abdominal enhanced CT scan were both performed before neoadjuvant chemotherapy; and (2) all patients received neoadjuvant chemotherapy before TME. Exclusion criteria were: (1) familial polyposis; (2) history of neoadjuvant CRT for other malignant tumors; (3) CT and MRI revealed incomplete images prior to neoadjuvant chemotherapy. Image quality was poor, and artifacts were obvious, which could not be used for image segmentation and radiomic feature extraction and analysis; and (4) clinical, laboratory, and pathology data were incomplete. The patient selection process is summarized in Figure 1.

***Neoadjuvant chemotherapy protocol***

The first chemotherapy course adopted the CapeOx plan (oxaliplatin 30 mg/m², day 1 and capecitabine 850-1000 mg/m², bid, day 1-14). With no break time after the first course, the second to fourth courses adopted the CapeOx plan with sequential oral apatinib 250 mg qd for 10 consecutive days. There were breaks of 3 wk for the second to the fourth course; and 3 wk after the fourth course of neoadjuvant chemotherapy, TME surgery was performed.

***CT and MR imaging protocol***

Enhanced CT was performed using a 128-MDCT scanner (Somatom Definition AS+, Siemens Healthcare Sector, Forchheim, Germany) and a dual-source CT system (Somatom Definition Flash, Siemens Healthcare Sector, Forchheim, Germany). Both CT models had the same tube voltage (120 kV), tube current (200-210 mAs), and slice thickness (2 mm). Intravenous nonionic contrast material (1.2 mL/kg; omnipaque 300 mg/mL, GE Healthcare) was administered *via* the antecubital vein, using a power injector at a rate of 3 mL/s. The area of interest was located in the center of the abdominal aorta at the level of the abdominal trunk. With a trigger threshold of the aorta reaching 170 HU, the arterial phase (at the trigger) and the portal vein phase (30 s after the trigger) images were obtained.

MRI was performed using a 3.0-T magnet (Magnetom Skyra, Siemens Healthcare, Erlangen, Germany) with an 18-channel matrix coil. All patients underwent bowel preparation with antispasmodic medications before imaging. A routine clinical imaging protocol was performed including axial HR-T2WI and axial DWI MRI with apparent diffusion coefficient (ADC). Dynamic contrast-enhanced (DCE) images were obtained using a fat-suppressed 3D gradient-echo T1 weighted sequence (volumetric interpolated breath-hold examination, known as ‘VIBE’). Dynamic contrast-enhanced images were obtained using 3D T1-VIBE with a volumetric acquisition of the entire rectum that began simultaneously with the intravenous administration of gadolinium (0.5 mmol/mL; Omniscan, GE Healthcare, Cork, Ireland) followed by a 30 mL saline flush (3 mL/s). The entire volume was acquired in one second, and the acquisition was repeated over a one-minute scan time to acquire an exact evaluation of the medium contrast kinetics in the tumor tissue of all vascular phases. The MRI parameters at our institution are summarized inSupplementary Table 1.

***Assessment of extramural venous invasion***

The features of extramural venous invasion (EMVI) and tumor location were evaluated by two radiologists (with 8-12 years of experience in rectal cancer imaging) who were blinded to pathological results using a scoring system from 0 to 4[[24](#_ENREF_24)]. EMVI scoring from 0 to 2 was defined as negativity, and EMVI scoring from 3 to 4 was defined as positivity. Upon disagreement, they would reach a consensus through negotiation.

***Tumor segmentation, radiomics features extraction, and preprocessing***

The open source software ITK-SNAP (3.6.0, open source, www.itksnap.org) was used for image segmentation. Pre-treatment enhanced CT and MRI findings were analyzed by a radiologist (with 8 years of experience in rectal cancer imaging), and validated by a senior radiologist (with 12 years of experience in rectal cancer imaging) within 1-2 wk to calculate intraclass correlation coefficients (ICCs). Both radiologists were blinded to the histopathology results. The regions of interest (ROIs) were created manually using the enhanced CT, HR-T2WI, and last phase (60 s after contrast injection) images from DCE-T1 (DCE-T1-60s) and ADC data, including the whole tumor and excluding the intestinal lumen. ROIs of rectal tumors were manually drawn on each slice. In order to decrease data variability and make it easier to evaluate quantitative radiomic features, intensity normalization was performed to transform original CT and MR images into a similar intensity distribution[[25](#_ENREF_25)].

The 118 patients were randomly divided into a training set (*n* = 70) and a validation set (*n* = 48). A total of 396 radiomic features of each sequence were extracted from all CT and MR images using the in-house Artiﬁcial Intelligence Kit software v.3.0.0. Normalization of extracted features was performed in the ﬁrst step before feature selection. We replaced outliers with the median of the particular variance vector when the values reached beyond the range of the mean and standard deviation. In addition, we standardized the data in a speciﬁc interval. The standardized formula was as follows: (ﬁ-u)/std, where ﬁ represents a single characteristic datum, u is the average value of the data column, and std is the standard deviation of the data column.

***Radiomics feature selection***

Adding a prior feature ranking procedure may be helpful for improving final performance. Therefore, after elimination of redundant features and features with low reproducibility, we used a multivariate ranking method [minimum redundancy maximum relevance (mRMR)] to identify the most important features on the basis of a heuristic scoring criterion, and only the top ranked features were retained[[26-28](#_ENREF_26)]. The least absolute shrinkage and selection operator (LASSO) was then used for selection bias of the features from the 20 top ranked features. λ was the regularization parameter of LASSO regression and was selected when the ten-fold-cross-validation error was minimal.

***Using the balanced dataset***

Considering that the non-responders group contained fewer patients than the responders group, this might have an adverse impact on classiﬁer performance; thus, the synthetic minority oversampling technique was applied with the joint weighting of features in the optimal subset to generate samples from the minority group to balance the size of the majority group[[29-31](#_ENREF_29)]. The advantage of this method is to obtain synthetic samples that have similar attribution values to existing samples and are “not merely replications”, thus enhancing the representation of the minority group while retaining the original structure of the samples.

***Model building***

Finally, the most signiﬁcant features were determined to construct the radiomics model on the basis of logistic regression. We ﬁrst created ﬁve different models based on individual enhanced CT, MRI (DCE-T1, HR-T2WI, ADC), and EMVI, and then compared the performance of the models based on individual sequences and their combination. The best of these models was constructed into the multi-modal radiomics nomogram. Clinical risk factors were compared *via* univariate analysis, and variables with *P* < 0.05 were included in the clinical model. Models were trained using the repeated 10-fold-cross-validation method in the training set, and estimation performance was evaluated in the validation set.

***Reference standard and pathological assessment of response***

The reference standard was the histopathological results generated by assessing the basic histopathology of the tumor specimens after TME. Histopathological analysis was performed by specialized gastrointestinal histopathologists with more than 10 years of experience who was blinded to imaging findings. Pathological grading of primary tumor regression was defined according to the four-tier American Joint Committee on Cancer tumor regression grade (TRG) system[[32](#_ENREF_32)]. TRG 0-2 was defined as a response to neoadjuvant chemotherapy, and TRG 3 was defined as non-response.

***Statistical analysis***

Statistical analyses were performed with R software v. 3.4.3 (R Core Team, Vienna, Austria). Performance of the different models was assessed using the receiver operating characteristic curve (ROC) analysis, and demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots were used to graphically investigate the performance characteristics of the nomogram. The DeLong test was used for statistical comparison of the ROC curves. The *t* test or Mann-Whitney *U* test was performed to compare continuous variables, while a *χ*2 or Fisher’s exact test was used for classifying variables between groups. All statistical tests were two-sided, and a Bonferroni-corrected *P* value was used to identify the signiﬁcance of the feature by multiple comparisons.

**RESULTS**

***Patient characteristics***

In this study, we enrolled 118 LARC patients who underwent TME after neoadjuvant chemotherapy, including 38 (32.2%) non-responders (22 males, 16 females) and 80 (67.8%) responders (57 males, 23 females). The patients were randomly divided into the training set (*n* = 70) and the validation set (*n* = 48). Demographic and clinicopathological characteristics of the cohort are presented in Table 1**.** Univariate factor analysis showed statistically signiﬁcant differences in EMVI between the two groups (*P* < 0.001). There were no differences in gender, age, BMI, TNM stage[[3](#_ENREF_3)] (T, tumor; N, Lymph Node; M, Metastasis), carcinoembryonic antigen (CEA) level, Carbohydrate antigen 199 (CA199) level, and lesion region between the response and non-response groups.

***Performance of radiomics models and nomogram***

A total of 396 radiomic features of each sequence were extracted from all CT and MR images (42 ﬁrst-order histogram features, 334 second-order texture features, 9 morphological features, and 11 gray-level zone size matrix features). After elimination of redundant features and features with low reproducibility, 65 radiomic features, including 18 features from enhanced CT, 14 from HR-T2WI, 17 from ADC, and 16 from DCE-T1 (Supplementary Table 2) were used to build individual radiomics models. For the combined model, we used a multivariate ranking method (mRMR) to identify the most important features, and only the top ranked features were retained. The most signiﬁcant features were then investigated to construct the radiomics model on the basis of logistic regression. Finally, 13 radiomic features with non-zero coefficients (two features from enhanced CT, one from HR-T2WI, five from ADC, and five from DCE-T1) were selected to calculate the radiomics score. The names of the selected features can be found in Supplementary Table 2. The agreement between the two radiologists on selected radiomic features was considered excellent (ICC range: 0.654 to 0.923). The Lasso process is shown in Figure 3.

As shown in Table 2, for an individual sequence, the HR-T2WI model performed better (AUC = 0.859, ACC = 0.896) than the CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) models in the validation set. The combined radiomics model had a signiﬁcantly better performance than CT (*P* = 0.03), while no significant differences were found when compared with DCE-T1, HR-T2WI, and ADC in the training set (Figure 4A). In the validation set, the combined radiomics model (AUC = 0.908, ACC = 0.812) had a better performance than the individual DCE-T1, HR-T2WI, and ADC models, but the differences were not signiﬁcant. The EMVI model achieved a relatively low performance in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.578, ACC = 0.583) sets. When combined with radiomic features, the multi-modal radiomics model performed better, and reached an AUC of 0.925 and ACC of 0.886 in the training set **(**Figure 4B), and an AUC of 0.93 and ACC of 0.875 in the validation set. The comparisons of different radiomic feature model performances were presented in Supplementary Table 3.

For the clinical radiomics nomogram, EMVI features and the radiomics score were identified by univariate analysis (*P* < 0.05). In multivariable logistic regression analysis, the radiomics score [odds ratio (OR) =1.34, *P* < 0.001] and EMVI (OR = 6.72, *P* = 0.01) significantly predicted the clinical response of neoadjuvant chemotherapy for LARC. Therefore, the radiomics nomogram was constructed with the radiomics score and EMVI, and good agreement was found between the nomogram prediction and actual observation in the calibration plots (Hosmer-Lemeshow test; *P* = 0.17) (Figure 5).

**DISCUSSION**

Our study developed and validated a radiomics model that incorporated CT and MRI features for the noninvasive and individualized prediction of clinical response to neoadjuvant chemotherapy in patients with LARC. The combination of CT and MRI (DCE-T1, HR-T2WI, and ADC) features was associated with better performance than any individual sequence. In contrast, the clinical model based on EMVI showed relatively low performance. A multi-modal nomogram facilitated an easy and noninvasive estimation of clinical response to neoadjuvant chemotherapy. The proposed radiomics model performed well, thereby adding accuracy to decision-making and the clinical assessment of neoadjuvant chemotherapy for LARC.

Although neoadjuvant CRT has been considered the standard treatment option for LARC, the main target of radiotherapy is local control, and its effects on distant metastasis or overall survival are still controversial, especially in patients undergoing TME surgery[[33-35](#_ENREF_33)]. Moreover, the short- and long-term adverse effects of radiotherapy, such as urogenital anal dysfunction and occurrence of secondary cancer, are not negligible[[36-38](#_ENREF_36)]. Due to progress in new effective chemotherapy strategies, the concept of neoadjuvant chemotherapy without radiotherapy has emerged. Recently, several studies[[39-41](#_ENREF_39)] have evaluated the feasibility and efficacy of neoadjuvant chemotherapy for LARC, and the results were promising; therefore, neoadjuvant chemotherapy without radiotherapy was performed in our study.

Imaging examination plays a key role in the evaluation of response to neoadjuvant chemotherapy for LARC. Our study showed that MRI features of EMVI were significantly positive in the responder group compared with the non-responder group, which is consistent with the literature[[42](#_ENREF_42),[43](#_ENREF_43)]. However, there were still some limitations[[44](#_ENREF_44),[45](#_ENREF_45)] in the evaluation of EMVI using MRI: first, the limitation of MRI resolution ratio and scan slice thickness resulted in a poor display of small vessels, and the examination results of EMVI may be false-negatives. Second, some local advanced cancers are accompanied by high vein invasion or extensive destruction of the vascular wall and cell structure with no normal vascular structure. Furthermore, MRI may indicate positive EMVI findings, which might increase the false-negative rate of pathological diagnosis. Therefore, a more accurate model is needed to predict the efficacy of neoadjuvant chemotherapy for LARC.

Recently, several studies have reported that radiomic features based on CT and MRI showed a good relationship with tumor biological characteristics and heterogeneities, which was helpful in predicting the curative effect of neoadjuvant CRT for LARC[[21](#_ENREF_21),[22](#_ENREF_22),[46-48](#_ENREF_46)]. Most of the above studies aimed to predict patients with pathologic complete response (PCR) by radiomics analysis, so as to omit surgery and over-treatment. Under neoadjuvant therapy, the rate of PCR was low, ranging from 15-27%[[21](#_ENREF_21),[22](#_ENREF_22),[46-48](#_ENREF_46)], which indicated that approximately 80% of patients did not achieve PCR and possibly received surgical intervention. However, even without PCR, the patients achieved partial responsiveness and benefited from neoadjuvant CRT by shrinking the tumor and descending the tumor stage, which could improve resectability rate[[8](#_ENREF_8),[49](#_ENREF_49)]. According to the TRG, the response rate of neoadjuvant chemotherapy was up to 67.8%, which means that 32.2% of patients did not benefit from the therapeutic strategy, and suffered from side effects and pain due to systemic chemotherapy. Therefore, the purpose of our study was to differentiate clinical response (including complete and partial) from non-responding LARC patients receiving neoadjuvant chemotherapy.

Multiparametric MRI radiomic features were reported to hold potential in predicting non-responsiveness to neoadjuvant therapy in patients with LARC, which achieved an area under the ROC curve of 0.82-0.83[[9](#_ENREF_9),[10](#_ENREF_10)]. In the present study, the HR-T2WI model performed better (AUC 0.859, ACC 0.896) than the above. However, most studies adopted a single examination method, and did not integrate multimodal imaging examination methods. Our study combined enhanced CT with multiparameter MRI to construct a multi-modal model with higher prediction efficiency than a single radiomics model.

In the era of precision medicine, a single feature or model can no longer meet the requirements of individualized treatment. Only the comprehensive analysis of all potentially useful information can improve the accuracy of prediction and diagnosis. A recent study[[50](#_ENREF_50)] has shown that combining clinical variables with the radiomics model can improve predictive performance of neoadjuvant CRT for LARC. However, no differences were found in clinical variables of gender, age, BMI, TNM stage, CEA, CA199, and lesion region between responder and non-responder groups in our study. Thus, we created the multi-parameter radiomics model only combined with EMVI to build a comprehensive prediction model, which had the highest prediction value in the training (ROC 0.925) and validation (ROC 0.93) group, respectively. In addition, this prediction model was made into a visual nomogram, which calculated the specific probability of each patient's curative effect based on the sum of the scores of each risk factor, making it easier for clinicians to judge the specific situation of each patient, and provide personalized treatments for patients.

 There are several studies[[22](#_ENREF_22),[46](#_ENREF_46),[51-53](#_ENREF_51)] reporting the use of joint models to construct nomograms, which have achieved a considerable prediction of neoadjuvant CRT for LARC. However, most studies only used a single imaging method, such as CT, MRI, or ultrasound. In contrast, the present study created a prediction model combined with CT and MRI, which has been the routine imaging examination method recommended by guidelines. Therefore, our multi-modal radiomics prediction model is economical and easy for clinical practice. Besides, some studies evaluated F18-FDG PET/CT and/or MRI radiomic features, and reported a high predictive value for curative effect[[51](#_ENREF_51),[54](#_ENREF_54)]; however, F18-FDG PET examination is expensive and difficult to popularize.

 Our research has several limitations. First, due to its retrospective design, there might be selection bias, although the patients were continuously enrolled. Second, the sample size was small as the neoadjuvant chemotherapy protocol is new in our hospital, and has not yet been widely used. Therefore, the results of the present study remain to be proven using different protocols of neoadjuvant chemotherapy or CRT. Third, some biological characteristics such as overexpression of human epidermal growth factor receptor 2 and Ki-67 were reported to have good prediction of response to neoadjuvant chemotherapy[[55-57](#_ENREF_55)]; however, in our study, the above biological markers were not available in all included patients. Thus, the multi-modal nomogram combined with biological characteristics is desirable in the future.

In conclusion, the findings of this study showed that the multi-modal nomogram established by radiomics of preoperative CT and MRI adds accuracy to prediction and could contribute to the personalized selection of neoadjuvant chemotherapy for LARC.

**ARTICLE HIGHLIGHTS**

***Research background***

Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging.

***Research motivation***

Several studies have reported that there were still 7-37% of LARC patients who do not respond to neoadjuvant CRT, which may not only increase CRT-related side effects and economic burden, but also delay surgery time. Therefore, it is necessary to identify which patients can benefit from neoadjuvant CRT treatment.

***Research objectives***

To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC.

***Research methods***

This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set (*n* = 70) and a validation set (*n* = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve (ROC) analysis and was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram.

***Research results***

Eighty of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC 0.859, ACC 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion (EMVI) detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.812, ACC = 0.792) sets. The combined radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation.

***Research conclusions***

A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC.

***Research perspectives***

Some biological characteristics such as overexpression of human epidermal growth factor receptor 2 and Ki-67 were reported to have good prediction of response to neoadjuvant chemotherapy; however, in our study, the above biological markers were not available in all included patients. Thus, the multi-modal nomogram combined with biological characteristics is desirable in the future.

**REFERENCES**

1 **Edwards BK**, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* 2010; **116**: 544-573 [PMID: 19998273 DOI: 10.1002/cncr.24760]

2 **Sauer R**, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004; **351**: 1731-1740 [PMID: 15496622 DOI: 10.1056/NEJMoa040694]

3 **Benson AB**, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018; **16**: 874-901 [PMID: 30006429 DOI: 10.6004/jnccn.2018.0061]

4 **Maas M**, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet Oncol* 2010; **11**: 835-844 [PMID: 20692872 DOI: 10.1016/S1470-2045(10)70172-8]

5 **Habr-Gama A**, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg* 2004; **240**: 711-7; discussion 717-8 [PMID: 15383798 DOI: 10.1097/01.sla.0000141194.27992.32]

6 **Påhlman L**, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, Ojerskog B, Damber L, Johansson R. The Swedish rectal cancer registry. *Br J Surg* 2007; **94**: 1285-1292 [PMID: 17661309 DOI: 10.1002/bjs.5679]

7 **Bosset JF**, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med* 2006; **355**: 1114-1123 [PMID: 16971718 DOI: 10.1056/NEJMoa060829]

8 **Rödel C**, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol* 2012; **13**: 679-687 [PMID: 22627104 DOI: 10.1016/S1470-2045(12)70187-0]

9 **Yang C**, Jiang ZK, Liu LH, Zeng MS. Pre-treatment ADC image-based random forest classifier for identifying resistant rectal adenocarcinoma to neoadjuvant chemoradiotherapy. *Int J Colorectal Dis* 2020; **35**: 101-107 [PMID: 31786652 DOI: 10.1007/s00384-019-03455-3]

10 **Zhou X**, Yi Y, Liu Z, Cao W, Lai B, Sun K, Li L, Zhou Z, Feng Y, Tian J. Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer. *Ann Surg Oncol* 2019; **26**: 1676-1684 [PMID: 30887373 DOI: 10.1245/s10434-019-07300-3]

11 **Park IJ**, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. *J Clin Oncol* 2012; **30**: 1770-1776 [PMID: 22493423 DOI: 10.1200/JCO.2011.39.7901]

12 **Janssen MH**, Ollers MC, Riedl RG, van den Bogaard J, Buijsen J, van Stiphout RG, Aerts HJ, Lambin P, Lammering G. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. *Int J Radiat Oncol Biol Phys* 2010; **77**: 392-399 [PMID: 19646825 DOI: 10.1016/j.ijrobp.2009.04.030]

13 **Engelen SM**, Beets-Tan RG, Lahaye MJ, Lammering G, Jansen RL, van Dam RM, Konsten J, Leijtens JW, van de Velde CJ, Beets GL. MRI after chemoradiotherapy of rectal cancer: a useful tool to select patients for local excision. *Dis Colon Rectum* 2010; **53**: 979-986 [PMID: 20551748 DOI: 10.1007/DCR.0b013e3181dc64dc]

14 **Intven M**, Reerink O, Philippens ME. Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation. *J Magn Reson Imaging* 2015; **41**: 1646-1653 [PMID: 25124320 DOI: 10.1002/jmri.24718]

15 **De Felice F**, Magnante AL, Musio D, Ciolina M, De Cecco CN, Rengo M, Laghi A, Tombolini V. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. *Eur J Surg Oncol* 2017; **43**: 1324-1329 [PMID: 28363512 DOI: 10.1016/j.ejso.2017.03.010]

16 **Gillies RJ**, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. *Radiology* 2016; **278**: 563-577 [PMID: 26579733 DOI: 10.1148/radiol.2015151169]

17 **Beig N**, Khorrami M, Alilou M, Prasanna P, Braman N, Orooji M, Rakshit S, Bera K, Rajiah P, Ginsberg J, Donatelli C, Thawani R, Yang M, Jacono F, Tiwari P, Velcheti V, Gilkeson R, Linden P, Madabhushi A. Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas. *Radiology* 2019; **290**: 783-792 [PMID: 30561278 DOI: 10.1148/radiol.2018180910]

18 **Sidhu HS**, Benigno S, Ganeshan B, Dikaios N, Johnston EW, Allen C, Kirkham A, Groves AM, Ahmed HU, Emberton M, Taylor SA, Halligan S, Punwani S. "Textural analysis of multiparametric MRI detects transition zone prostate cancer". *Eur Radiol* 2017; **27**: 2348-2358 [PMID: 27620864 DOI: 10.1007/s00330-016-4579-9]

19 **Ueno Y**, Forghani B, Forghani R, Dohan A, Zeng XZ, Chamming's F, Arseneau J, Fu L, Gilbert L, Gallix B, Reinhold C. Endometrial Carcinoma: MR Imaging-based Texture Model for Preoperative Risk Stratification-A Preliminary Analysis. *Radiology* 2017; **284**: 748-757 [PMID: 28493790 DOI: 10.1148/radiol.2017161950]

20 **Lakhman Y**, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow RA, Abu-Rustum NR, Hricak H, Sala E. Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis. *Eur Radiol* 2017; **27**: 2903-2915 [PMID: 27921159 DOI: 10.1007/s00330-016-4623-9]

21 **De Cecco CN**, Ciolina M, Caruso D, Rengo M, Ganeshan B, Meinel FG, Musio D, De Felice F, Tombolini V, Laghi A. Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: initial experience. *Abdom Radiol (NY)* 2016; **41**: 1728-1735 [PMID: 27056748 DOI: 10.1007/s00261-016-0733-8]

22 **Liu Z**, Zhang XY, Shi YJ, Wang L, Zhu HT, Tang Z, Wang S, Li XT, Tian J, Sun YS. Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. *Clin Cancer Res* 2017; **23**: 7253-7262 [PMID: 28939744 DOI: 10.1158/1078-0432.CCR-17-1038]

23 **Provenzale D**, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klapman JB, Larson DW, Lazenby AJ, Llor X, Lynch PM, Mikkelson J, Ness RM, Slavin TP, Sugandha S, Weiss JM, Dwyer MA, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. *J Natl Compr Canc Netw* 2018; **16**: 939-949 [PMID: 30099370 DOI: 10.6004/jnccn.2018.0067]

24 **Smith NJ**, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. *Br J Surg* 2008; **95**: 229-236 [PMID: 17932879 DOI: 10.1002/bjs.5917]

25 **Kickingereder P**, Götz M, Muschelli J, Wick A, Neuberger U, Shinohara RT, Sill M, Nowosielski M, Schlemmer HP, Radbruch A, Wick W, Bendszus M, Maier-Hein KH, Bonekamp D. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response. *Clin Cancer Res* 2016; **22**: 5765-5771 [PMID: 27803067 DOI: 10.1158/1078-0432.CCR-16-0702]

26 **Parmar C**, Grossmann P, Bussink J, Lambin P, Aerts HJWL. Machine Learning methods for Quantitative Radiomic Biomarkers. *Sci Rep* 2015; **5**: 13087 [PMID: 26278466 DOI: 10.1038/srep13087]

27 **Parmar C**, Grossmann P, Rietveld D, Rietbergen MM, Lambin P, Aerts HJ. Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer. *Front Oncol* 2015; **5**: 272 [PMID: 26697407 DOI: 10.3389/fonc.2015.00272]

28 **Peng H**, Long F, Ding C. Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. *IEEE Trans Pattern Anal Mach Intell* 2005; **27**: 1226-1238 [PMID: 16119262 DOI: 10.1109/TPAMI.2005.159]

29 **Feng Z**, Rong P, Cao P, Zhou Q, Zhu W, Yan Z, Liu Q, Wang W. Machine learning-based quantitative texture analysis of CT images of small renal masses: Differentiation of angiomyolipoma without visible fat from renal cell carcinoma. *Eur Radiol* 2018; **28**: 1625-1633 [PMID: 29134348 DOI: 10.1007/s00330-017-5118-z]

30 **Xu X**, Liu Y, Zhang X, Tian Q, Wu Y, Zhang G, Meng J, Yang Z, Lu H. Preoperative prediction of muscular invasiveness of bladder cancer with radiomic features on conventional MRI and its high-order derivative maps. *Abdom Radiol (NY)* 2017; **42**: 1896-1905 [PMID: 28217825 DOI: 10.1007/s00261-017-1079-6]

31 **Xu X**, Zhang X, Tian Q, Zhang G, Liu Y, Cui G, Meng J, Wu Y, Liu T, Yang Z, Lu H. Three-dimensional texture features from intensity and high-order derivative maps for the discrimination between bladder tumors and wall tissues via MRI. *Int J Comput Assist Radiol Surg* 2017; **12**: 645-656 [PMID: 28110476 DOI: 10.1007/s11548-017-1522-8]

32 **Trakarnsanga A**, Gönen M, Shia J, Nash GM, Temple LK, Guillem JG, Paty PB, Goodman KA, Wu A, Gollub M, Segal N, Saltz L, Garcia-Aguilar J, Weiser MR. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. *J Natl Cancer Inst* 2014; **106** [PMID: 25249540 DOI: 10.1093/jnci/dju248]

33 **Peeters KC**, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. *Ann Surg* 2007; **246**: 693-701 [PMID: 17968156 DOI: 10.1097/01.sla.0000257358.56863.ce]

34 **Abraha I**, Aristei C, Palumbo I, Lupattelli M, Trastulli S, Cirocchi R, De Florio R, Valentini V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. *Cochrane Database Syst Rev* 2018; **10**: CD002102 [PMID: 30284239 DOI: 10.1002/14651858.CD002102.pub3]

35 **De Caluwé L**, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. *Cochrane Database Syst Rev* 2013; CD006041 [PMID: 23450565 DOI: 10.1002/14651858.CD006041.pub3]

36 **Birgisson H**, Påhlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. *J Clin Oncol* 2005; **23**: 6126-6131 [PMID: 16135478 DOI: 10.1200/JCO.2005.02.543]

37 **Peeters KC**, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. *J Clin Oncol* 2005; **23**: 6199-6206 [PMID: 16135487 DOI: 10.1200/JCO.2005.14.779]

38 **Parc Y**, Zutshi M, Zalinski S, Ruppert R, Fürst A, Fazio VW. Preoperative radiotherapy is associated with worse functional results after coloanal anastomosis for rectal cancer. *Dis Colon Rectum* 2009; **52**: 2004-2014 [PMID: 19934922 DOI: 10.1007/DCR.0b013e3181beb4d8]

39 **Hasegawa S**, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, Yamaguchi T, Nishitai R, Manaka D, Kato S, Kadokawa Y, Yamanokuchi S, Kawamura J, Zaima M, Kyogoku T, Kanazawa A, Mori Y, Kanai M, Matsumoto S, Sakai Y. A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. *Ann Surg Oncol* 2017; **24**: 3587-3595 [PMID: 28685354 DOI: 10.1245/s10434-017-5967-3]

40 **Koike J**, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Hisada M, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Shiokawa H, Ogawa S, Itabashi M, Kameoka S. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial. *Cancer Chemother Pharmacol* 2017; **79**: 519-525 [PMID: 28150022 DOI: 10.1007/s00280-017-3243-7]

41 **Patel UB**, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Martin N, Estevan R, Fernandez-Martos C. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. *Ann Oncol* 2017; **28**: 344-353 [PMID: 28426108 DOI: 10.1093/annonc/mdw616]

42 **Liang P**, Nakada I, Hong JW, Tabuchi T, Motohashi G, Takemura A, Nakachi T, Kasuga T, Tabuchi T. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: its impact on prognosis. *Ann Surg Oncol* 2007; **14**: 470-477 [PMID: 17103258 DOI: 10.1245/s10434-006-9189-3]

43 **Suzuki T**, Sadahiro S, Tanaka A, Okada K, Saito G, Kamijo A, Akiba T, Kawada S. Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer. *J Surg Oncol* 2014; **109**: 659-664 [PMID: 24375387 DOI: 10.1002/jso.23550]

44 **Siddiqui MRS**, Simillis C, Hunter C, Chand M, Bhoday J, Garant A, Vuong T, Artho G, Rasheed S, Tekkis P, Abulafi AM, Brown G. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. *Br J Cancer* 2017; **116**: 1513-1519 [PMID: 28449006 DOI: 10.1038/bjc.2017.99]

45 **Sohn B**, Lim JS, Kim H, Myoung S, Choi J, Kim NK, Kim MJ. MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer. *Eur Radiol* 2015; **25**: 1347-1355 [PMID: 25500963 DOI: 10.1007/s00330-014-3527-9]

46 **Chee CG**, Kim YH, Lee KH, Lee YJ, Park JH, Lee HS, Ahn S, Kim B. CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: A potential imaging biomarker for treatment response and prognosis. *PLoS One* 2017; **12**: e0182883 [PMID: 28797063 DOI: 10.1371/journal.pone.0182883]

47 **Nie K**, Shi L, Chen Q, Hu X, Jabbour SK, Yue N, Niu T, Sun X. Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI. *Clin Cancer Res* 2016; **22**: 5256-5264 [PMID: 27185368 DOI: 10.1158/1078-0432.CCR-15-2997]

48 **Horvat N**, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ, Petkovska I. MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. *Radiology* 2018; **287**: 833-843 [PMID: 29514017 DOI: 10.1148/radiol.2018172300]

49 **Aschele C**, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol* 2011; **29**: 2773-2780 [PMID: 21606427 DOI: 10.1200/JCO.2010.34.4911]

50 **Dinapoli N**, Barbaro B, Gatta R, Chiloiro G, Casà C, Masciocchi C, Damiani A, Boldrini L, Gambacorta MA, Dezio M, Mattiucci GC, Balducci M, van Soest J, Dekker A, Lambin P, Fiorino C, Sini C, De Cobelli F, Di Muzio N, Gumina C, Passoni P, Manfredi R, Valentini V. Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. *Int J Radiat Oncol Biol Phys* 2018; **102**: 765-774 [PMID: 29891200 DOI: 10.1016/j.ijrobp.2018.04.065]

51 **Giannini V**, Mazzetti S, Bertotto I, Chiarenza C, Cauda S, Delmastro E, Bracco C, Di Dia A, Leone F, Medico E, Pisacane A, Ribero D, Stasi M, Regge D. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. *Eur J Nucl Med Mol Imaging* 2019; **46**: 878-888 [PMID: 30637502 DOI: 10.1007/s00259-018-4250-6]

52 **Zhao RS**, Wang H, Zhou ZY, Zhou Q, Mulholland MW. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. *Dis Colon Rectum* 2014; **57**: 388-395 [PMID: 24509465 DOI: 10.1097/DCR.0000000000000022]

53 **Tsai C**, Hague C, Xiong W, Raval M, Karimuddin A, Brown C, Phang PT. Evaluation of endorectal ultrasound (ERUS) and MRI for prediction of circumferential resection margin (CRM) for rectal cancer. *Am J Surg* 2017; **213**: 936-942 [PMID: 28391975 DOI: 10.1016/j.amjsurg.2017.03.029]

54 **Lovinfosse P**, Polus M, Van Daele D, Martinive P, Daenen F, Hatt M, Visvikis D, Koopmansch B, Lambert F, Coimbra C, Seidel L, Albert A, Delvenne P, Hustinx R. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer. *Eur J Nucl Med Mol Imaging* 2018; **45**: 365-375 [PMID: 29046927 DOI: 10.1007/s00259-017-3855-5]

55 **Meng X**, Xia W, Xie P, Zhang R, Li W, Wang M, Xiong F, Liu Y, Fan X, Xie Y, Wan X, Zhu K, Shan H, Wang L, Gao X. Preoperative radiomic signature based on multiparametric magnetic resonance imaging for noninvasive evaluation of biological characteristics in rectal cancer. *Eur Radiol* 2019; **29**: 3200-3209 [PMID: 30413959 DOI: 10.1007/s00330-018-5763-x]

56 **Martin V**, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras KT, Mazzucchelli L, Frattini M, Cappuzzo F. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. *Br J Cancer* 2013; **108**: 668-675 [PMID: 23348520 DOI: 10.1038/bjc.2013.4]

57 **Imaizumi K**, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, Sasaki T, Nishizawa Y, Taketomi A, Ito M, Nakatsura T. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. *Cancer Sci* 2020; **111**: 23-35 [PMID: 31660687 DOI: 10.1111/cas.14223]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of West China Hospital of Sichuan University.

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December 30, 2019

**First decision:** February 16, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Morelli L **S-Editor:** Wang YQ **L-Editor:** Filipodia **E-Editor:**

**Figure Legends**



**Figure 1 Flowchart of patient inclusion and exclusion.** LARC: Locally advanced rectal cancer; nCT: Neoadjuvant chemotherapy; TME: Total mesorectal excision; WCH: West China Hospital; CT: Computed tomography; MRI: Magnetic resonance imaging.



**Figure 2 A 56-year-old male with locally advanced rectal cancer.** A-C: Representative manual segmentation of the whole lesion in the axial dynamic contrast enhanced T1 images and enhanced computed tomography. Dotted lines represent the delineations of the regions of interest used to derive the radiomics features; D: Three-dimensional volumetric reconstruction of the segmented lesion.



**Figure 3 Texture feature selection using the least absolute shrinkage and selection operator binary logistic regression model.** A: Tuning parameter *λ* selection in the least absolute shrinkage and selection operator model used 10-fold cross-validation *via* minimum criteria. Area under the receiver operating characteristic curve was plotted versus the log *λ*. Dotted vertical lines were drawn at the optimal values using the minimum criteria. A *λ* value of -5.47, with log *λ*, according to 10-fold cross-validation; B: Least absolute shrinkage and selection operator coefficient profiles of the 20 top ranked texture features. A coefficient profile plot was produced against the log *λ* sequence. A vertical line was drawn at the value selected using 10-fold cross-validation, where optimal *λ* resulted in 13 nonzero coefficients.



**Figure 4** **Receiver operating characteristic curves in the training set.** A: Combined radiomics model [area under the curve (AUC) = 0.908, accuracy (ACC) = 0.812] achieved a better performance than individual computed tomography, dynamic contrast enhanced T1 images, high resolution T2-weighted imaging and apparent diffusion coefficient models; B: The extramural venous invasion model achieved relatively low performance in the training (AUC = 0.73, ACC = 0.714) set. In contrast, the multi-modal radiomics model (AUC = 0.925, ACC = 0.886) and combined radiomics model (AUC = 0.921, ACC = 0.886) performed better. CRM: Combined radiomics model; DCE-T1: Dynamic contrast enhanced T1 images; HR-T2WI: High resolution T2-weighted imaging; ADC: Apparent diffusion coefficient; CT: Computed tomography; MRM: Multi-modal radiomics model; EMVI: Extramural venous invasion.



**Figure 5 Development of predictive nomograms.** A: From each variable location on the corresponding axis, a line was drawn straight upward to the point axis and a point was obtained. After adding up all points, a line from the total points axis was drawn to the bottom line to determine the probability of response to neoadjuvant chemotherapy; B: Calibration curves for the radiomics nomogram in the training and validation cohort. The actual outcome of response to neoadjuvant chemotherapy is represented on the y-axis, and the predicted probability is represented on the x-axis. The closer the fit of the diagonal red and blue lines to the ideal grey line indicates the predictive accuracy of the nomogram. EMVI: Extramural venous invasion.

**Table 1 Clinical characteristics of patients in training and validation cohorts, *n* (%)**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Training cohort, *n* = 70** | **Validation cohort, *n* = 48** |
| **Response, *n* = 48** | **Non-response, *n* = 22** | ***P* value** | **Response, *n* = 32** | **Non-response, *n* = 16** | ***P* value** |
| T3 | 9 (18.8) | 0 (0) | 0.002 | 9 (28.1) | 0 (0) | 0.03 |
| T4a | 31 (64.6) | 10 (45.5) | 16 (50) | 8 (50) |
| T4b | 8 (16.7) | 12 (54.6) | 7 (21.9) | 8 (50) |
| N0 | 8 (16.7) | 1 (4.6) | 0.4 | 6 (18.8) | 2 (12.5) | 0.6 |
| N1 | 26 (54.2) | 13 (59.1) | 13 (40.6) | 9 (56.3) |
| N2 | 14 (29.2) | 8 (36.4) | 13 (40.6) | 5 (31.3) |
| Site: ultralow | 2 (4.2) | 1 (4.55) | 0.2 | 4 (12.5) | 1 (6.3) | 0.01 |
| Site: low | 34 (70.8) | 12 (54.6) | 21 (65.6) | 5 (31.3) |
| Site: high | 12 (25) | 9 (40.9) | 7 (21.9) | 10 (62.5) |
| EMVI positive  | 33 (68.8) | 5 (22.7) | < 0.001 | 24 (75) | 2 (12.5) | < 0.001 |
| EMVI negative | 15 (31.3) | 17 (77.3) | 8 (25) | 14 (87.5) |
| Female | 14 (29.2) | 10 (45.5) | 0.2 | 9 (28.1) | 6 (37.5) | 0.5 |
| Male | 34 (70.8) | 12 (54.6) | 23 (71.9) | 10 (62.5) |
| CEA ≤ 3.4 | 32 (66.7) | 14 (63.6) | 0.8 | 21 (65.6) | 12 (75) | 0.5 |
| CEA > 3.4 | 16 (33.3) | 8 (36.4) | 11 (34.4) | 4 (25) |
| CA199 ≤ 22 | 39 (81.3) | 19 (86.4) | 0.6 | 29 (90.6) | 14 (87.5) | 0.7 |
| CA199 > 22 | 9 (18.8) | 3 (13.6) | 3 (9.4) | 2 (12.50) |
| Age in yr | 59.2 ± 9.7 | 54.8 ± 10.5 | 0.09 | 60.8 ± 9.6 | 55.3 ± 11.1 | 0.08 |
| BMI in kg/m2 | 22.9 ± 3.2 | 23.1 ± 3.2 | 0.8 | 22.8 ± 3.4 | 23.3 ± 2.9 | 0.6 |
| Hb in g/L | 134.8 ± 20.5 | 127.9 ± 19.5 | 0.2 | 131.4 ± 19.5 | 127.1 ± 22.2 | 0.5 |

Site: ultralow: Lower margin of tumor involves anal canal; Site low: Lower margin of tumor is below [peritoneal](file:///C%3A/Program%2520Files%2520%28x86%29/Youdao/Dict/8.5.3.0/resultui/html/index.html#/javascript:;) [reflection](file:///C%3A/Program%2520Files%2520%28x86%29/Youdao/Dict/8.5.3.0/resultui/html/index.html#/javascript:;); Site: high: Lower margin of tumor is above [peritoneal](file:///C%3A/Program%2520Files%2520%28x86%29/Youdao/Dict/8.5.3.0/resultui/html/index.html#/javascript:;) [reflection](file:///C%3A/Program%2520Files%2520%28x86%29/Youdao/Dict/8.5.3.0/resultui/html/index.html#/javascript:;); EMVI: Extramural venous invasion; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen199; BMI: Body mass index; Hb: Hemoglobin.

**Table 2 Performance of optimal radiomic signatures**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **AUC** | **95%CI** | **Cut-off** | **ACC** | **Specificity** | **Sensitivity** |
| EMVI |
| Training | 0.73 | 0.619-0.842 | 0.331 | 0.714 | 0.688 | 0.773 |
| Validation | 0.578 | 0.426-0.731 |  | 0.583 | 0.594 | 0.562 |
| CT |
| Training | 0.809 | 0.745-0.872 | 0.5 | 0.818 | 0.875 | 0.742 |
| Validation | 0.766 | 0.632-0.899 |  | 0.792 | 0.844 | 0.688 |
| DCE-T1 |
| Training | 0.848 | 0.79-0.907 | 0.5 | 0.818 | 0.875 | 0.742 |
| Validation | 0.812 | 0.688-0.937 |  | 0.854 | 0.938 | 0.688 |
| HR-T2WI |
| Training | 0.845 | 0.786-0.903 | 0.5 | 0.857 | 0.932 | 0.758 |
| Validation | 0.859 | 0.746-0.973 |  | 0.896 | 0.969 | 0.75 |
| ADC |
| Training | 0.847 | 0.789-0.904 | 0.5 | 0.844 | 0.83 | 0.864 |
| Validation | 0.828 | 0.71-0.946 |  | 0.833 | 0.844 | 0.812 |
| CRM |
| Training | 0.921 | 0.842-1 | 0.318 | 0.886 | 0.854 | 0.955 |
| Validation | 0.908 | 0.823-0.994 |  | 0.812 | 0.812 | 0.812 |
| MRM |
| Training | 0.925 | 0.845-1 | 0.447 | 0.886 | 0.896 | 0.864 |
| Validation | 0.93 | 0.86-1 |  | 0.875 | 0.875 | 0.875 |

EMVI: Extramural venous invasion; CT: Computed tomography; DCE-T1: Dynamic contrast enhanced T1 images; HR-T2WI: High resolution T2-weighted imaging; ADC: Apparent diffusion coefficient; CRM: Combined radiomic model; MRM: Multi-modal radiomics model; AUC: Area under the curve; CI: Confidence interval; ACC: Accuracy.